TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC

Bernuth, Amelie von; Ribbat‐Idel, Julika; Klapper, Luise; Jagomast, Tobias; Rades, Dirk; Leichtle, Anke; Pries, Ralph; Bruchhage, Karl‐Ludwig; Perner, Sven; Offermann, Anne; Sailer, Verena; Idel, Christian

doi:10.3390/ijms24065140

Cited by 6 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The institutional ethic committee at the University Hospital Rostock approved the study (number A2022-0120), which was conducted in accordance with the Declaration of Helsinki of 1975. An independent, well-described cohort from primary HNSCCs was used as a control group to validate our prognostic findings [26][27][28].…”

Section: Patient Cohort and Multi Tumor Tissue Blocksmentioning

confidence: 99%

Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response

Becker,

Kluge,

Schofeld

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

The 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) is approximately 65%. In addition to radio-chemotherapy, immunotherapy is an approach in the treatment of advanced HNSCC. A better understanding of the immune context would allow personalized treatment by identifying patients who are best suited for different treatment options. In our discovery cohort, we evaluated the expression profiles of CMTM6, PD-L1, CTLA-4, and FOXP3 in 177 HNSCCs from Caucasian patients of all tumor stages and different treatment regimens, correlating marker expression in tumor and immune cells with outcomes. Patients with CMTM6high-expressing tumors had a longer overall survival regardless of treatment. This prognostic benefit of CMTM6 in HNSCC was validated in an independent cohort. Focusing on the in the discovery cohort (n = 177), a good predictive effect of CMTM6high expression was seen in patients receiving radiotherapy (p = 0.07; log rank), but not in others. CMTM6 correlated with PD-L1, CTLA-4 and FOXP3 positivity, with patients possessing CMTM6high/FOXP3high tumors showing the longest survival regardless of treatment. In chemotherapy-treated patients, PD-L1 positivity was associated with longer progression-free survival (p < 0.05). In the 27 patients who received immunotherapy, gene expression analysis revealed lower levels of CTLA-4 and FOXP3 with either partial or complete response to this treatment, while no effect was observed for CMTM6 or PD-L1. The combination of these immunomodulatory markers seems to be an interesting prognostic and predictive signature for HNSCC patients with the ability to optimize individualized treatments.

show abstract

Section: Patient Cohort and Multi Tumor Tissue Blocksmentioning

confidence: 99%

Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response

Becker,

Kluge,

Schofeld

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some E3 ubiquitin ligases have been identified as potential prognostic and immunological biomarker in some cancer diseases. 98,99 As mentioned in the previous sections, several E3 ubiquitin ligases were found to be affected under pathological conditions, including Cdh1, 36 HRD1, 57 TRAF6, 32 and TRIM proteins, 37,38,94 but whether they can serve as clinical diagnostic markers still remain to be evaluated. Such information can aid clinicians in making well-informed decisions regarding patient management and treatment strategies.…”

Section: Clinical Significance Of E3 Ubiquitin Ligase In Vascular Dis...mentioning

confidence: 97%

E3 Ubiquitin Ligases in Endothelial Dysfunction and Vascular Diseases: Roles and Potential Therapies

Wang

Zhan

Wang

et al. 2023

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Ubiquitin E3 ligases are a structurally conserved family of enzymes that exert a variety of regulatory functions in immunity, cell death, and tumorigenesis through the ubiquitination of target proteins. Emerging evidence has shown that E3 ubiquitin ligases play crucial roles in the pathogenesis of endothelial dysfunction and related vascular diseases. Here, we reviewed the new findings of E3 ubiquitin ligases in regulating endothelial dysfunction, including endothelial junctions and vascular integrity, endothelial activation, and endothelial apoptosis. The critical role and potential mechanism of E3 ubiquitin ligases in vascular diseases, such as atherosclerosis, diabetes, hypertension, pulmonary hypertension, and acute lung injury, were summarized. Finally, the clinical significance and potential therapeutic strategies associated with the regulation of E3 ubiquitin ligases were also proposed.

show abstract

Multifaceted role of TRIM28 in health and disease

Maghsoudloo,

Mokhtari,

Jamali

et al. 2024

MedComm

View full text Add to dashboard Cite

The TRIM (tripartite motif) family, with TRIM28 as a key member, plays a vital role in regulating health and disease. TRIM28 contains various functional domains essential for transcriptional regulation, primarily through its interaction with KRAB‐ZNF proteins, which influence chromatin remodeling and gene expression. Despite extensive research, the precise mechanisms by which TRIM28 impacts health and disease remain elusive. This review delves into TRIM28’s multifaceted roles in maintaining health, contributing to a variety of diseases, and influencing cancer progression. In cancers, TRIM28 exhibits a dual nature, functioning as both a tumor promoter and suppressor depending on the cellular context and cancer type. The review also explores its critical involvement in processes such as DNA repair, cell cycle regulation, epithelial‐to‐mesenchymal transition, and the maintenance of stem cell properties. By uncovering TRIM28’s complex roles across different cancers and other diseases, this review underscores its potential as a therapeutic target. The significance of TRIM28 as a versatile regulator opens the door to innovative therapeutic strategies, particularly in cancer treatment and the management of other diseases. Ongoing research into TRIM28 may yield key insights into disease progression and novel treatment options.

show abstract

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC

Cited by 6 publications

References 46 publications

Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response

Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response

E3 Ubiquitin Ligases in Endothelial Dysfunction and Vascular Diseases: Roles and Potential Therapies

Multifaceted role of TRIM28 in health and disease

Contact Info

Product

Resources

About